Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

被引：0
|
作者：
Li, Jian
Chi, Ping
Kang, Yoon-Koo
Cao, Hui
George, Suzanne
Zhang, Jun
Zhang, Jian
Hu, Kang
Zhang, Lijia
Xu, Yanhua
机构：
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Minist Educ, Lab Carcinogenesis & Translat Res,Dept Gastrointe, Beijing, Peoples R China
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[4] Shanghai Jiao Tong Univ, Renji Hosp, Dept Gastrointestinal Surg, Sch Med, Shanghai, Peoples R China
[5] Dana Farber Canc Inst, Dept Med Oncol, Sarcoma Ctr, Boston, MA USA
[6] Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Chongqing, Peoples R China
[7] Fudan Univ, Dept Med Oncol, Phase 1 Clin Trial Ctr, Shanghai Canc Hosp, Shanghai, Peoples R China
[8] Ningbo Newbay Technol Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11518
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A first-in-human phase I trial of NB003, a potent and selective KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)
    Chi, P.
    Shen, L.
    Li, J.
    Zhang, J.
    Hu, K.
    Zhang, L.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1031 - S1031
  • [2] Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
    George, S.
    Heinrich, M.
    Chi, P.
    Razak, A.
    von Mehren, M.
    Gordon, M.
    Ganjoo, K. N.
    Somaiah, N.
    Trent, J. C.
    Ahnert, J. Rodon
    Wolf, J.
    Ruiz-Soto, R.
    Rosen, O.
    Janku, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
    Chi, Ping
    Janku, Filip
    Heinrich, Michael
    Ganjoo, Kristen
    Gelderblom, Hans
    Gordon, Michael
    Jones, Robin
    Razak, Albiruni
    Trent, Jonathan
    von Mehren, Margaret
    Hu, Simin
    Su, Ying
    Ruiz-Soto, Rodrigo
    George, Suzanne
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [4] A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
    Wagner, A. J.
    Yazji, S.
    Morgan, J. A.
    Choy, E.
    George, S.
    Hohos, M.
    O'Mara, M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [5] Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.
    Janku, Filip
    Razak, Albiruni Ryan Abdul
    Gordon, Michael S.
    Brooks, David Glenn
    Flynn, Daniel Lee
    Kaufman, Michael
    Pitman, Jama
    Smith, Bryan Douglas
    Somaiah, Neeta
    De Groot, John Frederick
    Chen, Guo
    Jennings, Julia
    Salah, Samer
    Westwood, Deb
    Gerstenberger, Eric
    Rosen, Oliver
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
    Janku, F.
    Bauer, S.
    Shoumariyeh, K.
    Jones, R. L.
    Spreafico, A.
    Jennings, J.
    Psoinos, C.
    Meade, J.
    Ruiz-Soto, R.
    Chi, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S896 - S897
  • [7] KIT mutation analysis in NF-1 patients with multiple gastrointestinal stromal tumors (GIST)
    Yantiss, RK
    Rosenberg, AR
    Antonescu, CR
    LABORATORY INVESTIGATION, 2003, 83 (01) : 137A - 137A
  • [8] KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs):: a population-based study
    Braconi, C.
    Bracci, R.
    Bearzi, I.
    Bianchi, F.
    Costagliola, A.
    Catalani, R.
    Mandolesi, A.
    Ranaldi, R.
    Galizia, E.
    Cascinu, S.
    Rossi, G.
    Giustini, L.
    Latini, L.
    Valeri, N.
    Cellerino, R.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 706 - 710
  • [9] Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)
    Heinrich, M.
    Jones, R.
    Schoffski, P.
    Bauer, S.
    von Mehren, M.
    Eskens, F.
    Cassier, P.
    Mir, O.
    Shi, H.
    Alvarez-Diez, T.
    Healy, M. E.
    Wolf, B.
    George, S.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S4 - S4
  • [10] A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
    Ganjoo, K. N.
    Villalobos, V. M.
    Kamaya, A.
    Fisher, G. A.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    D'Adamo, D.
    McMillan, A.
    Demetri, G. D.
    George, S.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 236 - 240
12345